Hope Rugo

RT @ErikaHamilton9: #ESMOBreast25 is next month. Love this "digestible" breast only meeting with the benefits of extra interaction with al…

Congratulations to my UCSF and all colleagues for their grant award! Most importantly thanks to this amazing advocacy group that is changing the path forward for BC! METAvivor Announces 2024 MBC Research Awards | METAvivor ⁦⁦⁦@UCSFCancer⁩ https://t.co/aPgYRfdKcQ

Wow. I am so grateful for our BC community for supporting our good friend and colleague ⁦@dradityabardia⁩ and his family during this terrible time. Please donate!! Fundraiser by Mina Sedrak : Support the Bardia Family After Palisades Fire. https://t.co/UQxSyF5imb

Beautiful article highlighting the amazing fabric of medical providers. A story of courage, hope & commitment. With admiration. L.A. Oncologist's Family Is Evacuated, Follows Him to Hospital to Help. ⁦@OncoAlert⁩ ⁦@cityofhope⁩ #lafire https://t.co/UdWRZgETjW

So proud of @KelseyNatsuhara presenting her retrospective study on outcome with TDXd retreat after grade 1 ILD in the RW setting at the @UCSFCancer med onc retreat. Now expanding to a multicenter study! Beautiful job! https://t.co/IKyqOQ46SH

Very interesting & important project. The ABC Global Alliance & Lisbon Nova Uni developed a model to calculate the financial impact of flexible labor/work-related laws, to dxallow patients living with ABC to continue to work if they wish to do so. https://t.co/T6V16tFiod

RT @OncBrothers: 1. #EUROPA: Ph III, ET vs XRT after surgery in ≥70 yrs HR+ luminal A-like early breast cancer. Median F/U: 2yrs - Treatm…

Nothing final yet! Still digesting and discussing all the data. Thanks @OncoAlert for connecting our incredible community and #SABCS24 for an excellent congress. Congrats to @VKaklamani, Kate Lathrop, Carlos Arteaga and team!

OncoAlert @OncoAlert

Dear Colleagues An amazing #SABCS24 and our thanks to our collaborators at @SABCSSanAntonio For yet another amazing Symposium ✅ 70 million impressions ✅ 11.5k posts ✅ 1.7k Participants WE ARE ALL @OncoAlert 🚨 @matteolambe 🇮🇹 @ErikaHamilton9 🇺🇸 @hoperugo 🇺🇸 @JaniceTNBCmets https://t.co/oBctixVp54

Indeed great work and presentation. This data suggests we need to rethink study designs. Sequencing preop therapy based on response and correlating with biology given heterogeneity seems critical. #SABCS24 @OncoAlert

Sara Tolaney @stolaney1

Fabulous presentation by @elmayermd on preop dostarlimab + niraparib in ER+ gBRCAm breast cancer n=18 pCR 16.7% (RCB 0/1 44%) @SABCSSanAntonio #SABC24 @OncoAlert @DFCI_BreastOnc @TheTBCRC https://t.co/9d9ko6Gwar

Very intriguing data. PLAN B did not show this association. Benefit crossed menopausal status so perplexing. Additional biomarkers for anthra benefit an age old question and still important. #SABCS24 @OncoAlert

Stephanie Graff, MD, FACP, FASCO @DrSGraff

In TAILORx (LN- HR+) pts w/ RS≥31 addition of anthracycline results in benefit in 5-yr DRFI (5% HR 0.32) vs TC 📏benefit most clear in tumor >2 cm ↗️Increasing RS≥31 corresponded to increasing benefit of addition of anthracycline #SABCS24 @SABCSSanAntonio @OncoAlert https://t.co/lb1O9Ilgpv

The key messages here are important. 1. Ki67 suppression with 3-4 week pre op ET for N0-1 BC predicts excellent outcome with ET alone. And in premenop women too. 2. Nabpac less neuropathy. Consider change for early sx with pac. #SABCS24 @OncoAlert

Nadia Harbeck,MD PhD @Prof_Nadia_H

S. Kümmel presented final data from WSG ADAPT HR+ HER2-. Similar survival between dose-dense taxane regimens using nab-paclitaxel or packitaxel and anthraclines. Patients with N0-1 RS <26 and endocrine response hat excellent 5yr ddfs >96% with endocrine therapy alone. #OncoAlert https://t.co/o7S62UjsLl

#SABCS24 Shao presents CAMrelief trial. Camrelizumab IO China with NAC. 441 patients powered for pCR. Improved pCR for TNBC. EFS early. No new safety issues. Nice data but we MUST power these trials for EFS although costly and with risk. Pub today in JAMA @OncoAlert https://t.co/Ftdu8xo9KE

#SABCS24 Chuck Geyer presents long awaited atezo TNBC neoadj trial. Endpt EFS, 1550 pts. Med FU 46.9 mo. No diff in EFS in pCR and non pCR but sign diff in N+, T>3cm, hi TILs. 6% higher pCR. Neg study but 59% node neg! @OncoAlert https://t.co/Nucht7LJy6

Adding handle for the excellent author @MsNanchen

Hope Rugo @hoperugo

#SABCS24 Nan Chen presents anthracycline impact in RS>31 in pts on TailoRx. Most got TC. Marked benefit of DFS in AC/T in high RS, OS trend but 2 early. A important in LN- HR+ high RS disease. Practice influencing data! @OncoAlert https://t.co/navGU96XDS

#SABCS24 Nan Chen presents anthracycline impact in RS>31 in pts on TailoRx. Most got TC. Marked benefit of DFS in AC/T in high RS, OS trend but 2 early. A important in LN- HR+ high RS disease. Practice influencing data! @OncoAlert https://t.co/navGU96XDS

Yes beautiful talk. RFI not interpretable tho. Numbers too small. CI wide. NS. Many issues well discussed by Ian Krop. CtDNA should only be used as part of a clinical trial!! @OncoAlert #SABCS24 listen to ctDNA Ed session 12-10! https://t.co/1jXJkSIGfr

OncLive.com @OncLive

ZEST trial: Beautiful talk by Dr Turner: high rate of radiographic recurrence at the time of ctDNA detection in patients with TNBC. RFI: 5.4 to 11.4 months with Niraparib. #bcsm #SABCS24 @SABCSSanAntonio @mazo_md

RT @stolaney1: Excellent poster discussion by @antgiorda including discussion of OS subgroup data from KN522 (poster by @RebeccaDSing ) @S…